First experience of using 3D-therapy OBV/PTV/r + DSV in treating a patient with HCV 1b, liver cirrhosis Child-Pugh A and multiple myeloma in Russia (case report)

• Sulima D.L.
• Dmitry A. Lioznov
• Larionov V.А.
• Gavrilenko А.N.
• Mikhailov А.М.
• Gorchakova О.V.
• Mikitenko Е.V.

AbstractThe clinical case of 12 weeks completely oral interferon-free 3D-therapy with Ombitasvir, Paritaprevir/ Ritonavir and Dasabuvir (OBV/PTV/r + DSV) and ribavirin in real clinical practice in the difficult patient with HCV infection 1b genotype, compensated liver cirrhosis (Child-Pugh A) associated with multiple myeloma (syn.: myeloma, Rustitskogo-Kahler's disease, plasmacytoma) is presented. It was clinically manifested by the musculoskeletal pain syndrome and was diagnosed immediately before the start of 3D-therapy. Treatment required constant supervision of an oncologist-hematologist and monitoring of drug-drug interactions. It was effective (RVR1, SVR12, SVR24, SVR48, SVR80 in blood plasma and bone marrow aspirate) and well tolerated. Within 80 weeks after the completion of 3D-therapy course, the patient maintains a stable normalization of levels of alpha-fetoprotein (6.47 ng/ml), enzymes ALT/AST/gamma-GT and laboratory indicators of the main hepatic-cellular functions. Up to date, the patient has received several courses of chemotherapy and two surgeries of bone marrow autotransplantation, which allowed to achieve stabilization of myeloma.

Keywords:OBV/PTV/r + DSV, ombitasvir/paritaprevir/ritonavir + dasabuvir, real clinical practice, HCV 1b genotype, HCV liver cirrhosis, multiple myeloma

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)